Sensitive ELISA detection of amyloid‐β protofibrils in biological samples
- 9 June 2007
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 103 (1), 334-345
- https://doi.org/10.1111/j.1471-4159.2007.04759.x
Abstract
Amyloid-beta (Abeta) protofibrils are known intermediates of the in vitro Abeta aggregation process and the protofibrillogenic Arctic mutation (APPE693G) provides clinical support for a pathogenic role of Abeta protofibrils in Alzheimer's disease (AD). To verify their in vivo relevance and to establish a quantitative Abeta protofibril immunoassay, Abeta conformation dependent monoclonal antibodies were generated. One of these antibodies, mAb158 (IgG2a), was used in a sandwich ELISA to specifically detect picomolar concentrations of Abeta protofibrils without interference from Abeta monomers or the amyloid precursor protein (APP). The specificity and biological significance of this ELISA was demonstrated using cell cultures and transgenic mouse models expressing human APP containing the Swedish mutation (APPKN670/671ML), or the Swedish and Arctic mutation in combination. The mAb158 sandwich ELISA analysis revealed presence of Abeta protofibrils in both cell and animal models, proving that Abeta protofibrils are formed not only in vitro, but also in vivo. Furthermore, elevated Abeta protofibril levels in the Arctic-Swedish samples emphasize the usefulness of the Arctic mutation as a model of enhanced protofibril formation. This assay provides a novel tool for investigating the role of Abeta protofibrils in AD and has the potential of becoming an important diagnostic assay.Keywords
This publication has 60 references indexed in Scilit:
- Attenuated amyloid-β aggregation and neurotoxicity owing to methionine oxidationNeuroReport, 2007
- The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic miceNeurobiology of Aging, 2006
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Unique Physicochemical Profile of β-Amyloid Peptide Variant Aβ1–40E22G Protofibrils: Conceivable Neuropathogen in Arctic Mutant CarriersJournal of Molecular Biology, 2004
- Soluble Arctic amyloid β protein inhibits hippocampal long‐term potentiation in vivoEuropean Journal of Neuroscience, 2004
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature, 2002
- Protofibrils, the unifying toxic molecule of neurodegenerative disorders?Nature Neuroscience, 2001
- The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formationNature Neuroscience, 2001
- Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's DiseaseThe American Journal of Pathology, 1999